D.A. Davidson analyst Linda Bolton Weiser maintained a Hold rating on Prestige Consumer Healthcare (PBH – Research Report) today. The company’s shares closed yesterday at $58.85.
According to TipRanks, Bolton Weiser is a 3-star analyst with an average return of 1.1% and a 45.64% success rate. Bolton Weiser covers the Consumer Cyclical sector, focusing on stocks such as Inter Parfums, Coty, and WW International.
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Prestige Consumer Healthcare with a $79.00 average price target.
See today’s best-performing stocks on TipRanks >>
The company has a one-year high of $68.54 and a one-year low of $52.90. Currently, Prestige Consumer Healthcare has an average volume of 224.3K.
Based on the recent corporate insider activity of 52 insiders, corporate insider sentiment is neutral on the stock.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Prestige Consumer Healthcare (PBH) Company Description:
Prestige Consumer Healthcare, Inc. engages in the marketing, sale, and distribution of pharmaceutical drugs and consumer products. It operates through the following segments: North American OTC Healthcare, and International OTC Healthcare. The North American and International OTC Healthcare segments manages the following brands: BC/Goody’s, Beano, Boudreaux’s Butt Paste, Chloraseptic, Clear Eyes, Compound W, Debrox, DenTek, Dramamine, Efferdent, Fess, Fleet, Gaviscon, Hydralyte, Luden’s, Monistat, Nix, Pedia-Lax, and Summer’s Eve. The company was founded in 1996 and is headquartered in Tarrytown, NY.
Read More on PBH:
- Prestige Consumer sees FY24 EPS $4.27-$4.32 , consensus $4.31
- Prestige Consumer reports Q2 EPS $1.07, consensus $1.07
- Prestige Consumer Healthcare Inc. Reports Second Quarter Fiscal 2024 Results
- PBH Earnings this Week: How Will it Perform?
- Prestige Consumer Healthcare Inc. to Release Fiscal 2024 Second Quarter Earnings Results
